GILD or AMGN: Which Is the Better Value Stock Right Now?

Core Viewpoint - Gilead Sciences (GILD) is currently viewed as a more attractive undervalued stock option compared to Amgen (AMGN) based on various financial metrics and earnings outlook [1][7]. Valuation Metrics - GILD has a forward P/E ratio of 14.24, while AMGN's forward P/E is 15.10, indicating GILD may be undervalued relative to AMGN [5]. - The PEG ratio for GILD is 0.73, suggesting a favorable valuation when considering expected earnings growth, compared to AMGN's PEG ratio of 2.60 [5]. - GILD's P/B ratio stands at 7.26, significantly lower than AMGN's P/B ratio of 28.50, further supporting GILD's valuation as more attractive [6]. Earnings Outlook - GILD is experiencing an improving earnings outlook, which enhances its position in the Zacks Rank model, indicating a positive trend in earnings estimates [3][7].